This is the authors' abstract. We don't add key points for this paper.
The humanized monoclonal very late antigen 4 (VLA-4) antibody natalizumab is FDA approved for the treatment of patients with multiple sclerosis and Crohn's disease. In this review we focus on its role in the context of hematopoietic stem cell transplantation and stem cell diseases. The use of natalizumab alone or in combination with either cytotoxic drugs or other antibodies might be a new modality for stem cell mobilization and a therapeutic option for patients with hematologic malignancies.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Neumann et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: